Detection method of IMP type carbapenemase drug-resistant gene

Through enzymatic recombinant isothermal amplification technology, the rapid detection of IMP genes at room temperature has been solved, and the problems of complex, time-consuming and insufficient specificity of detection methods in the existing technology have been solved, and high sensitivity and high specificity of IMP gene detection is achieved, which is suitable for On-site application at room temperature.

CN119082335APending Publication Date: 2024-12-06SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +1
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411503536.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-25
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing IMP gene detection methods have problems such as complex operation, long time, high cost and insufficient specificity, especially in on-site detection of room temperature, which is difficult to achieve rapid, sensitive and efficient detection.

Method used

Using enzymatic recombinant isothermal amplification technology (ERA), using specific primers and fluorescent probes, the IMP gene was quickly detected at room temperature through constant temperature amplification technology. The reaction temperature was 36℃~42℃ and the reaction time was 15-60 In minutes, combined with fluorescence signal detection, a detection method with simple operation, short time consuming, high sensitivity and strong specificity is provided.

Benefits of technology

It realizes rapid detection of IMP genes, with a sensitivity of 0.01ng/μL, high specificity, and no cross-reaction with other carbapenemase subtype genes. It is suitable for on-site detection of room temperature, simplifying the operation process and reducing the detection cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005103195490000071
    Figure BDA0005103195490000071
  • Figure BDA0005103195490000091
    Figure BDA0005103195490000091
  • Figure BDA0005103195490000101
    Figure BDA0005103195490000101
Patent Text Reader

Abstract

The invention provides a detection method of an IMP type carbapenemase drug-resistant gene, and a specific primer pair and a probe used in the detection method. Specifically, the specific primer pair and the probe disclosed by the invention can efficiently and specifically amplify the IMP gene, the sensitivity of the IMP gene reaches 0.01 ng / mu L, and the IMP gene has no cross reaction with NDM, VIM, OXA and KPC genomic DNA. The detection method avoids aerosol pollution, is simple to operate, can rapidly, conveniently and highly sensitively detect the IMP gene under an isothermal condition, and can be used for rapidly screening and detecting carbapenem antibiotic drug-resistant bacteria producing IMP.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and in particular, the present invention relates to a method for detecting an IMP gene based on ERA technology. Background Art

[0002] Bacterial resistance has become a major challenge in the field of global public health, among which the infection caused by carbapenem-resistant Enterobacteriaceae (CRE) is the most serious. Carbapenem antibiotics have become one of the most important antibacterial drugs for the treatment of serious bacterial infections due to their broad antibacterial spectrum and strong antibacterial activity. However, with the excessive use of carbapenem antibiotics in clinical practice in recent years, many bacteria can hydrolyze carbapenem antibiotics by producing carbapenemases and inactivate them, leading to the production of carbapenem-resistant Enterobacteriaceae (CRE), which is becoming a widespread epidemic worldwide.

[0003] IMP is a common metallo-β-lactamase with strong carbapenem hydrolysis activity in clinical practice. Due to the presence of gene elements that mediate transfer in its resistance gene, it is easy to transfer between different bacteria, resulting in the widespread spread of carbapenem resistance. Therefore, the fastest and most effective way to monitor this type of IMP enzyme-producing strain is to detect its resistance gene.

[0004] At present, the main technology used to detect IMP genes is molecular biological detection. According to the amplification temperature, it can be divided into variable temperature amplification technology and isothermal amplification detection technology, including polymerase chain reaction (PCR), fluorescent quantitative PCR, loop-mediated isothermal amplification PCR (LAMP), etc. Variable temperature amplification PCR requires a relatively expensive thermal cycler, which is complex and time-consuming to operate. As a common isothermal amplification technology, LAMP technology still has certain shortcomings and deficiencies, such as complex primer design, reaction temperature of about 60°C and long reaction time, which limits its application in on-site detection.

[0005] Therefore, there is an urgent need to develop a detection method for IMP genes that is simple to operate, time-saving, highly sensitive, highly specific, and suitable for on-site detection at room temperature. Summary of the invention

[0006] The object of the present invention is to provide a method for detecting an IMP gene which is simple to operate, short in time, highly sensitive, highly specific and suitable for on-site detection at room temperature.

[0007] In the first aspect of the present invention, a non-diagnostic and non-therapeutic method for amplifying the IMP gene is provided, the amplification method comprising the steps of: performing amplification in a reaction system, the reaction system containing a specific primer pair for amplifying the IMP gene, the primer pair comprising: a sequence as shown in SEQ ID NO:7, and a sequence as shown in SEQ ID NO:4.

[0008] In another preferred embodiment, the minimum detection concentration of the method is 0.005-0.015 ng / μL.

[0009] In another preferred embodiment, the minimum detection concentration of IMP in the method is 0.01 ng / μL.

[0010] In another preferred embodiment, the reaction system further comprises a probe, and the probe comprises a sequence as shown in SEQ ID NO:1.

[0011] In another preferred embodiment, the probe is labeled with a fluorescent group and a quencher group.

[0012] In another preferred embodiment, the 5' end of the probe is labeled with a fluorescent gene FAM, and the 3' end is labeled with a quenching group BHQ.

[0013] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 5 or its complementary chain.

[0014] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 8 or its complementary chain.

[0015] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.

[0016] In another preferred embodiment, the method further comprises: performing an amplification reaction in another positive (control) reaction system or a negative (control) reaction system.

[0017] In another preferred embodiment, the positive reaction system contains genomic DNA of drug-resistant bacteria of Citrobacter freundii expressing IMP.

[0018] In another preferred embodiment, the reaction system further comprises amplification elements such as DNA polymerase, single-stranded binding protein, endonuclease IV, recombinase and auxiliary protein.

[0019] In another preferred embodiment, the method further comprises the step of detecting the fluorescent signal emitted by the specific probe during or after the amplification reaction.

[0020] In another preferred embodiment, the method is enzymatic isothermal amplification (ERA).

[0021] In another preferred embodiment, the reaction reagents of the ERA further include: one or more of a universal solvent for the ERA reaction system, an activator, a fluorescent amplification reagent, and ddH2O.

[0022] In another preferred embodiment, the reaction temperature of the ERA isothermal amplification is 36°C to 42°C, preferably 37°C to 39°C.

[0023] In another preferred embodiment, the reaction time of the ERA isothermal amplification is 15-60 minutes, preferably 15-20 minutes.

[0024] In a second aspect of the present invention, a non-diagnostic detection method for an IMP gene is provided, the method comprising the steps of:

[0025] (a) amplifying the sample to be tested using the method described in the first aspect of the present invention; and

[0026] (b) Perform signal detection.

[0027] In another preferred embodiment, the method further comprises processing the sample to be tested to obtain genomic DNA, and then amplifying the target DNA by the method described in the first aspect of the present invention.

[0028] In another preferred embodiment, the sample to be tested is the nucleic acid of a human excrement sample.

[0029] In another preferred embodiment, the method further comprises setting up one or more control groups.

[0030] In another preferred example, the control group includes a negative control group and a positive control group.

[0031] In another preferred embodiment, the positive control group includes a drug-resistant strain of Citrobacter freundii that produces IMP.

[0032] In another preferred embodiment, the method includes qualitative detection and quantitative detection.

[0033] In another preferred embodiment, the minimum detection concentration of the method is 0.005-0.015 ng / μL.

[0034] In another preferred embodiment, the minimum detection concentration of the method is 0.01 ng / μL.

[0035] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.

[0036] In another preferred example, the detection includes fluorescence signal detection.

[0037] In another preferred embodiment, the fluorescence detection includes using a fluorescence quantitative PCR instrument or using a handheld fluorescence detector for real-time detection.

[0038] In a third aspect of the present invention, a detection kit for rapid detection of IMP gene is provided, the detection kit comprising:

[0039] a container, and a primer pair and a probe specific for the IMP gene in the container,

[0040] Wherein, the specific primer pair includes the sequence shown as SEQ ID NO:7 and the sequence shown as SEQ ID NO:4; and the probe includes the sequence shown as SEQ ID NO:1.

[0041] In another preferred embodiment, the detection kit further comprises elements such as DNA polymerase, single-strand binding protein, endonuclease IV, recombinase and auxiliary protein.

[0042] In another preferred example, the detection kit further comprises a sample processing reagent, and the sample processing reagent comprises a cell lysis solution, a nucleic acid extraction solution, a washing solution and the like.

[0043] In another preferred example, the detection kit further includes an ERA reaction reagent, and the ERA reaction reagent includes one or more of a universal dissolving agent, an activating agent, a fluorescent amplification reagent, and ddH2O.

[0044] In another preferred embodiment, the detection kit further includes an IMP positive control and an IMP negative control.

[0045] In another preferred embodiment, the detection kit further comprises an instruction manual, wherein the instruction manual is used to guide the detection of the IMP gene.

[0046] In a fourth aspect of the present invention, there is provided a use of the detection kit as described in the third aspect, for non-diagnostic and non-therapeutic detection of whether a sample to be tested contains IMP-type carbapenemase-resistant bacteria.

[0047] In another preferred embodiment, the sample to be tested is the nucleic acid of a human excrement sample.

[0048] In another preferred embodiment, the kit is used to identify whether the sample to be tested contains IMP-type carbapenemase-resistant bacteria. By detecting the IMP gene content C0 of the sample to be tested and the IMP gene content C1 in the negative control sample, if C0>C1 or C0 / C1>1.5, preferably>2, and more preferably>3, it indicates that the sample to be tested may contain IMP-type carbapenemase-resistant bacteria.

[0049] In another preferred embodiment, the kit is also used to evaluate the antibacterial effect of drugs against IMP-type carbapenemase-resistant bacteria. The IMP gene content Z0 in the sample after the drug treatment of IMP-type carbapenemase-resistant bacteria and the IMP gene content Z1 in the sample without the use of the above-mentioned drug are detected; if the ratio of Z0 / Z1 is ≤2 / 3, preferably ≤1 / 2, and more preferably ≤1 / 3, it indicates that the drug has the effect of inhibiting IMP-type carbapenemase-resistant bacteria.

[0050] In a fifth aspect of the present invention, a specific primer pair for amplifying the IMP gene is provided, the primer pair comprising a sequence as shown in SEQ ID NO:7 and a sequence as shown in SEQ ID NO:4.

[0051] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 5 or its complementary chain.

[0052] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 8 or its complementary chain.

[0053] In another preferred example, the primer pair includes a sequence as shown in SEQ ID NO: 2 or its complementary chain, and a sequence as shown in SEQ ID NO: 10 or its complementary chain.

[0054] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 shows the results of the ERA method for detecting the IMP gene in carbapenem-resistant Citrobacter freundii using 21 primer pairs: A. Primer pair A1-A8; B. Primer pair B1-B8; C. Primer pair C1-C5. The primer pair information is shown in Table 2.

[0056] Figure 2 Shown are the test results of the optimal primer pair for detecting different concentrations of Citrobacter freundii genomic DNA.

[0057] Figure 3 Shown are the test results of the optimal primer pair for detecting different concentrations of Citrobacter freundii genomic DNA in human feces.

[0058] Figure 4 The results of cross-reactivity specificity testing of the optimal primer pairs in different genomes are shown. DETAILED DESCRIPTION

[0059] After extensive and in-depth research and a large number of screenings, the inventors have developed a method for rapid detection of IMP genes based on enzymatic recombinant isothermal amplification (ERA). Experiments have shown that the method has a sensitivity of 0.01 ng / μL, high detection specificity, and no cross-reaction with NDM, VIM, OXA, and KPC genomic DNA, and can be used for rapid screening and detection of IMP-producing carbapenem-resistant bacteria. The present invention was completed on this basis.

[0060] the term

[0061] In order to make the present invention more easily understood, some technical and scientific terms are specifically defined below. Unless otherwise specifically defined herein, all other technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs.

[0062] As used herein, the terms "comprise", "include", and "contain" are used interchangeably and include not only closed definitions, but also semi-closed and open definitions. In other words, the terms include "consisting of", "consisting essentially of".

[0063] Primers and probes

[0064] As used herein, the term "primers specific for the IMP gene" refers to primers (pairs) that amplify products having complementary sequences of the IMP gene. Preferred primer sequences include a primer pair consisting of SEQ ID NO:7 and SEQ ID NO:4.

[0065] In the amplification method of the present invention, in addition to the primers, the reaction system may also include one or more probes, such as an IMP fluorescent probe, for detecting the amplification effect of the IMP gene. The probe has a FAM fluorescent group and a BHQ quenching group, and has a blocking group at the 3'-end to block the polymerase extension of the probe. A preferred detection probe of the present invention has a nucleotide sequence as shown in SEQ ID NO: 1.

[0066] In the present invention, many primer sequences were designed, and 21 primer pairs were formed by combining two of them. After a large number of experimental screenings, the combination of SEQ ID NO: 4 and SEQ ID NO: 7 with high specificity and high sensitivity was finally selected, and its sensitivity could reach 2.759 copies / μL.

[0067] ERA

[0068] Enzymatic Recombinase Amplification (ERA) is an isothermal amplification technology developed by Suzhou Xinda Gene Technology Co., Ltd. in China. Through genetic engineering, the multi-enzyme system of recombinase, exonuclease, polymerase, etc. is modified to establish a special amplification reaction system. At room temperature, the specific segment of trace DNA / RNA can be amplified billions of times within a few minutes. It has the advantages of being fast and simple, easy to operate, and having reliable results.

[0069] The present invention uses ERA to detect IMP genes, which includes, in addition to specific primers and probes, universal reaction reagents of ERA, including one or more of universal solvents, activators, fluorescent amplification reagents, and ddH2O. When other methods are used to detect IMP, the specific primers and probes of the present invention can also be used in combination with reaction reagents suitable for other methods to perform IMP detection.

[0070] IMP

[0071] IMP is a common metallo-β-lactamase with strong carbapenem hydrolysis activity in clinical practice and is one of the subtypes of carbapenemases. Carbapenemases also include OXA type, NDM type, KPC type, and VIM type.

[0072] In the present invention, "carbapenem antibiotic-resistant bacteria" and "carbapenemase-resistant bacteria" are used interchangeably to refer to bacteria that express carbapenemase and are resistant to carbapenem antibiotics.

[0073] The IMP-producing Citrobacter freundii drug-resistant strains involved in the embodiments of the present invention were donated by the First Affiliated Hospital of Nanchang University. The fecal samples of healthy volunteers were obtained from the Shanghai Institute of Biomedical Technology.

[0074] The 10 primers designed for the IMP gene of the present invention include: 3 upstream primers (SEQ ID NOs: 2-4), 7 downstream primers (SEQ ID NOs: 5-11), and 1 fluorescent probe (SEQ ID NO: 1), as shown in Table 1.

[0075] Table 1 Primer and probe sequences

[0076]

[0077] (FAM-dT)(THF)(BHQ1-dT) indicates that the probe consists of an oligonucleotide backbone consisting of a flanking FAM-dT fluorophore, a deoxynucleotide analog (tetrahydrofuran [THF] residue), and a BHQ1-dT quencher.

[0078] (C3-SPACER) here stands for: 3'-blocking group to block polymerase extension of the probe.

[0079] Detection Methods

[0080] The present invention provides a method for detecting an IMP gene, comprising amplifying a sample to be detected using the specific primers of the present invention; and

[0081] During or after the amplification reaction, the amplified product of the IMP gene is detected, for example, by detecting the fluorescent signal emitted by the specific probe.

[0082] The method may also optionally include setting up one or more control groups, such as an IMP positive control group, an IMP negative control group, and the like.

[0083] Preferably, the IMP positive control group is genomic DNA of drug-resistant Citrobacter freundii bacteria expressing IMP.

[0084] Preferably, the IMP negative control group is PCR water.

[0085] In the present invention, the detection method can be a conventional PCR method, or a different method such as real-time fluorescence PCR. Preferably, the present invention uses the ERA method.

[0086] Typically, the ERA method of the present invention comprises the following steps:

[0087] S1. DNA from stool samples was extracted using thermal lysis method as a template;

[0088] S2. Amplifying DNA in an ERA reaction system comprising specific primers and specific probes of the present invention;

[0089] S3. Signal detection is performed through the fluorescent signal carried by the specific probe.

[0090] Among them, the ERA reaction system also includes other ERA reaction reagents, such as universal solvent, activator, fluorescence amplification reagent, ddH2O, etc.

[0091] Detection Kits

[0092] The present invention also provides an IMP gene detection kit, which contains a specific detection reagent and can more accurately identify whether the sample to be tested contains carbapenemase-resistant bacteria, especially IMP-type carbapenemase-resistant bacteria. By detecting the IMP gene content C0 of the sample to be tested and the IMP gene content C1 in the negative control, if C0>C1 or C0 / C1>1.5, preferably>2, and more preferably>3, it indicates that the sample to be tested may contain IMP-type carbapenemase-resistant bacteria.

[0093] Preferably, the detection reagents of the detection kit of the present invention include specific primers, specific probes, reagents for preparing the ERA reaction system, and the like.

[0094] The detection reagent of the present invention further comprises a container and an instruction manual, wherein the container is used to contain the detection reagent, and the instruction manual is used to guide the use of the detection reagent.

[0095] Based on this kit, the present invention can further provide the antibacterial effect of the drug against IMP-type carbapenemase-resistant bacteria. After the drug treatment of IMP-type carbapenemase-resistant bacteria, the IMP gene content Z0 in the sample and the IMP gene content Z1 in the sample without the above drug are detected; if the ratio of Z0 / Z1 is ≤2 / 3, preferably ≤1 / 2, and more preferably ≤1 / 3, it indicates that the drug has the effect of inhibiting IMP-type carbapenemase-resistant bacteria.

[0096] Compared with the prior art, the advantages of the present invention are as follows:

[0097] 1. The technical solution provided by the present invention uses the IMP gene as the detection target, relies on enzymatic amplification reaction, uses a specific primer and probe combination, and completes the detection within 20 minutes through constant temperature amplification technology. It does not require a complicated sample DNA pretreatment process, does not require thermal deformation of the template, is easy to operate, and takes a short time.

[0098] 2. The reaction conditions of the technical solution of the present invention are 37-42°C, and the temperature control does not need to be particularly strict, nor does it need to set multiple parameters, and the energy consumption is low. Therefore, it is particularly suitable for on-site operation.

[0099] 3. The technical solution of the present invention uses fluorescence numerical interpretation results, eliminating the process of electrophoresis verification of PCR products and avoiding aerosol contamination.

[0100] 4. The specific primer pair and probe of the IMP gene of the present invention have extremely high sensitivity, with a minimum detection concentration of about 0.01 ng / μL. They also have high specificity and have no cross-reaction with other subtype genes of carbapenemase.

[0101] 5. The IMP gene detection kit of the present invention can be used as a reagent for detecting IMP genes in clinical specimens (excreta, etc.) or clinical isolates, and can be used in scientific research and clinical applications.

[0102] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0103] Example 1. Screening for the optimal primer pair for IMP gene specific amplification

[0104] Table 2 Primer pairs for detecting specific amplification of IMP genes

[0105]

[0106]

[0107] The upstream and downstream primers described in Table 1 were paired in pairs to form 21 primer pairs, as shown in Table 2. The drug-resistant strain of Citrobacter freundii producing IMP was used as the detection object to detect the effects of different primer pairs in the specific amplification of IMP gene, and SEQ ID NO: 1 was the probe sequence.

[0108] DNA sample preparation: The template DNA is the genomic DNA extracted from the above strains after culture. Specifically, the strains were cultured in brain heart infusion broth (BHI) medium containing ampicillin (50 μg / mL) at 37°C according to the standard protocol, and then Plasmid DNA Mini Kit I (D6942-01) was used to extract genomic DNA according to the instructions. The template DNA was diluted 10 times in a row, and the working concentration was 10.0 ng / μl.

[0109] ERA isothermal amplification: Amplification was performed using the ERA isothermal amplification reaction system. The 50ul amplification reaction system was constructed as follows:

[0110]

[0111] The amplification temperature was 37°C and the reaction lasted for 20 min.

[0112] Fluorescence detection: During the reaction, the GS8 fluorescence thermostatic amplification instrument was used to detect the change in fluorescence value, and the fluorescence was read every 30 seconds until the reaction was completed. On the fluorescence detector, the positive group showed an "S" curve with an exponential amplification trend; the negative group showed a flat horizontal straight line with no amplification trend; the TT (time threshold) value was 4 to 8 minutes. Parallel experiments were performed with different primer pairs to detect the fluorescence results.

[0113] The test results showed that: after a large number of screening, the following combination was screened out from 21 primer pair combinations: primer pair SEQ ID NO: 4 (F) + SEQ ID NO: 7 (R), which had good sensitivity and specificity (Figure 1).

[0114] Example 2. Minimum detection concentration of IMP gene

[0115] Select the following optimal primer pairs and probe sequences:

[0116] SEQ ID NO:4(F):5'-TTGTTTTGTAGCATTACTGCCGCAGGAGCGTCTT-3'

[0117] SEQ ID NO:7(R):5'-CAGATAGGCGTCAGTATTTACAAGAACCACCA-3'

[0118] SEQ ID NO:1(probe):5'-TTATGTATATTTTTGTTTTGTAGCATTACT(FAM-dT)(THF)(BHQ1-dT)GCAGGAGCGTCTTTG(C3-SPACER)-3'

[0119] The genomic DNA of Citrobacter freundii expressing IMP was used as a positive template, and PCR water was used as a negative control to perform ERA isothermal amplification to detect the detection limit of ERA. In this example, the thermal lysis method was used to extract DNA. The thermal lysis method was to culture Citrobacter freundii for 5 hours (the harvested cells were approximately equivalent to 10 8 CFU / mL), resuspend 15 μL of Citrobacter freundii cells in 150 μL of extraction buffer, vortex briefly, and then incubate at 95°C for 5 minutes. Take the buffer to dilute the pure genomic DNA of Citrobacter freundii 10 times continuously to obtain a DNA sample corresponding to a concentration range of 0.01-10 ng / μL. Take 2 μL of the lysate as the template DNA in this example. The reaction system is as described in Example 1. Parallel experiments are carried out with templates of different concentrations, and the fluorescence results are detected.

[0120] The results show that the IMP gene detection method of the present invention has an extremely low detection concentration of 0.01 ng / μL (i.e. 2.759 copies / μL). Figure 2 .

[0121] Example 3. IMP gene detection in human stool samples

[0122] A 1 g stool sample was collected using a sterile spatula, thawed on ice, and added to 10 ml of ice-cold phosphate-buffered saline (PBS). 900 μL of the stool suspension was transferred to a new Eppendorf tube and inoculated with 100 μL of an overnight culture of an IMP-producing Citrobacter freundii resistant strain to a level of 10 8 CFU / 1.0g feces. Take 15μL of the suspension and resuspend it in 150μL of extraction buffer E, vortex gently, and boil at 95℃ for 5 minutes to release DNA. Perform 10-fold gradient dilution of the obtained sample to obtain 10 8 ~10 5 CFU / 1.0g corresponding to the DNA sample. Take 2 μL of the lysate as the template DNA in this example. The reaction system is as described in Example 1, and the primer pair and probe sequence are as described in Example 2. Detect the fluorescence results.

[0123] The results showed that the detection method of the present invention is effective for human fecal samples (10 5 CFU / 1.0g, corresponding to 12.5CFU of Citrobacter freundii) is also effective, see Figure 3 .

[0124] Example 4. Optimal primer pairs and probe specificity for carbapenemase IMP gene

[0125] The optimal primer pair and probe sequence as described in Example 2 were selected, and genomic DNA samples containing different subtypes of carbapenemase (blaNDM, blaVIM, blaIMP, blaOXA, blaKPC) at a concentration of 20 ng were used to evaluate the specificity of the primer pair and probe combination in detecting the IMP gene. The reaction system is as described in Example 1. ddH2O was used for negative control to ensure that amplification would not occur in the absence of target DNA. The amplification temperature was 37°C, the reaction was 20 minutes, and the change in fluorescence was detected using a GS8 fluorescence thermostatic amplification instrument, and the fluorescence was read every 30 seconds.

[0126] The results showed that the amplification curve only appeared in IMP-positive DNA samples, and there was no cross-reaction with other carbapenemase subtype genes blaNDM, blaVIM, blaOXA, and blaKPC ( Figure 4 ), indicating that the primer pairs and probes for the IMP gene screened by the present invention have extremely high specificity.

[0127] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A non-diagnostic and non-therapeutic method for amplifying an IMP gene, characterized in that: The amplification method comprises the steps of: performing amplification in a reaction system, wherein the reaction system contains a specific primer pair for amplifying the IMP gene, and the primer pair comprises: a sequence as shown in SEQ ID NO:7, and a sequence as shown in SEQ ID NO:

4.

2. The method according to claim 1, characterized in that The method further comprises a probe comprising the sequence shown in SEQ ID NO:

1.

3. A non-diagnostic detection method for an IMP gene, characterized in that: The method comprises the steps of: (a) amplifying the sample to be tested using the method according to claim 1; and (b) Perform signal detection.

4. The method according to claim 3, characterized in that The method may further comprise an IMP negative control and / or an IMP positive control.

5. The method according to claim 3, characterized in that The sample to be tested is a human excrement sample.

6. The method according to claim 3, characterized in that The minimum detection concentration of the method is 0.005-0.015 ng / μL.

7. A detection kit for rapid detection of IMP gene, characterized in that: The detection kit comprises: a container, and a primer pair and a probe specific for the IMP gene in the container, Wherein, the primer pair includes the sequence shown as SEQ ID NO:7 and the sequence shown as SEQ ID NO:4; and the probe includes the sequence shown as SEQ ID NO:

1.

8. A use of the detection kit according to claim 7, characterized in that: Used for non-diagnostic and non-therapeutic detection of whether the test sample contains IMP-type carbapenemase-resistant bacteria.

9. The use according to claim 8, characterized in that The kit is also used to evaluate the antibacterial effect of drugs against IMP-type carbapenemase-resistant bacteria.

10. A specific primer pair for amplifying an IMP gene, characterized in that: The primer pair includes the sequence shown as SEQ ID NO:7 and the sequence shown as SEQ ID NO:4.

Citation Information

Patent Citations

  • Fluorescent ERA constant-temperature rapid detection kit for African swine fever viruses

    CN112176103A

  • Primer pair for rapidly detecting bovine nodular skin disease virus, probe and kit

    CN112941239A

  • Visual rapid detection method for tetrapod iridovirus 1 based on ERA technology as well as primer and probe for detection

    CN115820936A

  • White spot syndrome virus rapid detection method and kit based on ERA technology

    CN115948613A

  • Carbapenem drug resistance gene detection kit and application thereof

    CN116479148A